Summary of SOPHiA GENETICS FY Conference Call Company Overview - **Company**: SOPHiA GENETICS (NasdaqGS:SOPH) - **Industry**: Precision Medicine and Genomics - **Key Transition**: Jurgi Camblong will transition to Executive Chairman, with Ross Muken becoming CEO effective July 1, 2026 [4][6] Core Insights and Arguments Business Growth and Strategy - SOPHiA GENETICS has a network of nearly 1,000 customers across 70 countries, analyzing approximately 35,000 genomic profiles monthly [5] - The company is approaching $100 million in Annual Recurring Revenue (ARR) and aims for 20%-22% growth in 2026, an acceleration from high-teens growth [16][18] - Liquid biopsy is identified as a significant growth driver, with the U.S. market experiencing 50% volume growth [19][30] - The company is focusing on expanding its customer base in biopharma, which has faced challenges but is now seeing positive momentum [20][78] Market Position and Competitive Advantage - SOPHiA GENETICS aims to become the largest producer of precision medicine data globally, leveraging its extensive network and data capabilities [14] - The company is positioned to capitalize on the trend of hospitals bringing testing capabilities in-house, particularly for established tests with high clinical validity [26][35] - The average selling price (ASP) for data compute has increased from $50 to $170 per patient, with newer applications potentially reaching $300-$500 per patient [48][49] Technological Innovation - The company has been AI-native since its inception, utilizing machine learning to enhance data interpretation and diagnostic accuracy [54][55] - The ability to process diverse datasets allows for the development of sophisticated algorithms, providing a competitive edge over other players in the market [58] Future Outlook - The company envisions significant growth potential, aiming to transition from $100 million to billions in revenue over the next few years [86] - There is a focus on expanding into various phases of drug development, including patient stratification and real-world evidence [81][85] - The partnership with leading academic medical centers like MSK and MD Anderson is expected to enhance global reach and impact [70][71] Additional Important Points - The U.S. market is a key focus, with significant contracts and partnerships expected to drive growth [32][78] - The company is cautious about capital allocation, aiming for profitability within the next 18 months while still pursuing growth opportunities [85] - The competitive landscape includes entrenched players, but SOPHiA GENETICS is confident in its differentiated model and strategic positioning [78] This summary encapsulates the key points discussed during the SOPHiA GENETICS FY Conference Call, highlighting the company's growth trajectory, strategic initiatives, and competitive advantages in the precision medicine industry.

Core Insights - SOPHiA GENETICS SA is a key player in AI-driven precision medicine, focusing on enhancing healthcare outcomes through artificial intelligence [1] - The company reported financial challenges in its Q4 2025 earnings, with losses despite revenue growth [1] Financial Performance - For Q4 2025, SOPH reported an earnings per share (EPS) of -$0.28, missing the estimated EPS of -$0.25, indicating ongoing losses [2] - The company's revenue for the quarter was $21.7 million, exceeding the estimated $20.7 million, reflecting a 22% year-over-year increase [2] - SOPH's gross margin for Q4 2025 was 67.7% on a reported basis and 73.9% on an adjusted basis, showing scalability in its AI-native precision medicine platform [3] - The IFRS net loss for Q4 2025 increased by 27% to $19.2 million, while the adjusted EBITDA loss rose by 9% to $9.9 million [3][6] Annual Overview - For the full year 2025, SOPH achieved a revenue of $77.3 million, a 19% increase from the previous year [4] - The gross margin remained stable at 67.4% on a reported basis and improved to 74.2% on an adjusted basis [4] - The IFRS net loss for the year was $79 million, a 26% increase year-over-year, and the adjusted EBITDA loss was $41.5 million, up by 3% [4] Valuation Metrics - SOPH's price-to-sales ratio stands at about 3.99, indicating a high valuation relative to sales [5] - The enterprise value to sales ratio is approximately 3.74, reflecting the company's valuation relative to its sales [5] - The enterprise value to operating cash flow ratio is negative at around -7.15, indicating challenges in generating positive cash flow from operations [5] - Despite these challenges, SOPH maintains a strong current ratio of approximately 2.80, suggesting a solid ability to cover short-term liabilities with short-term assets [5]

Core Insights - SOPHiA GENETICS S.A. reported a strong Q3 performance with a 23% year-over-year revenue growth, driven by new customer signings and expansion within existing accounts [4][27][40] - The company raised its 2025 revenue guidance to a range of $75 million to $77 million, reflecting confidence in continued growth momentum [3][36] Customer Growth and Expansion - In Q3, SOPHiA signed 31 new customers, bringing the total for 2025 to 94, surpassing the previous year's total of 92 [3][17] - The company successfully expanded its offerings at existing institutions, including major deals with Gustave Roussy and New South Wales Pathology [2][5] Market Performance - U.S. revenue grew by 30% year-over-year, contributing significantly to overall growth [1][15] - EMEA region saw a 24% revenue growth, with notable contributions from the UK and Belgium, which grew by 120% and 70% respectively [14][15] Product Development and Innovation - The company highlighted the success of its liquid biopsy application, MSK Access, which is gaining traction among customers [5][7] - SOPHiA introduced a new technology called SOPHiA DDM Digital Twins, aimed at enhancing treatment decision-making for oncologists [9][10] Financial Performance - Total revenue for Q3 was $19.5 million, compared to $15.9 million in the same quarter last year, with gross profit increasing to $12.9 million [27][29] - Adjusted gross margin remained strong at 73.1%, despite a significant increase in data processed by the platform [11][29] Strategic Partnerships - The partnership with AstraZeneca is expected to enhance market access for liquid biopsy testing and contribute to drug development [7][21] - Collaborations with Myriad Genetics and ADAM Innovations are aimed at developing regulated companion diagnostics in the U.S. and Japan [7][21][63] Future Outlook - The company anticipates continued growth in 2026, driven by strong customer demand and the successful implementation of new applications [36][70] - SOPHiA is focused on optimizing costs while expanding its customer base and product offerings [12][38]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [29] - Full year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [33] - Adjusted gross margin for 2025 was 74.2%, an increase of 140 basis points from 72.8% in 2024 [35] - Annualized revenue churn was less than 1% for 2025, indicating strong customer retention [34] Business Line Data and Key Metrics Changes - Excluding biopharma, clinical revenue grew 31% year-over-year in Q4 2025 [16] - Hemato-oncology testing volumes grew 27% year-over-year in Q4 2025 [18] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [19] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4 2025, with clinical revenue up 35% year-over-year [17] - North America saw analysis volumes grow 45% year-over-year in Q4 2025 [17] - Asia Pacific revenue grew 44% in Q4 2025, driven by India and Australia [18] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives to modernize its platform [9][10] - New products like MSK-ACCESS and MSK-IMPACT are expected to drive growth in 2026 [19] - The company aims to achieve adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027 [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and customer signings [43] - The company anticipates a back-half weighted growth in 2026 due to new business coming online [39] - Management noted that the biopharma sector is expected to contribute positively to revenue in 2026 [60] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [10] - The company has raised $15.5 million in net proceeds through an at-the-market facility [32] Q&A Session Summary Question: Contributions from key growth drivers for 2026 - Management highlighted the ramping of MSK-ACCESS as a significant growth driver, with strong customer signings and volumes expected to increase [46][47] Question: Net dollar retention and cross-selling strength - Management noted that net dollar retention increased to 115%, driven by low churn and strong growth across various application sets [51][53] Question: Potential annual contribution from new pharma contracts - Management indicated that while the pharma business is expected to improve, it takes time to ramp up and contribute significantly to revenue [58][60] Question: Expansion potential with large health systems - Management expressed optimism about growing accounts materially over time, with significant expansion opportunities identified [62][64] Question: Volume price mix for 2026 guidance - Management expects ASPs to increase due to higher-priced tests, while also anticipating volume growth in regions with lower ASPs [68][70] Question: New CEO's approach and potential changes - The new CEO emphasized a focus on scaling the business and unlocking the full value of the platform, while maintaining a partnership with the outgoing CEO [71][73]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [30] - Full-year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [34] - Gross profit for Q4 2025 was $14.7 million, up 21% from $12.1 million in the prior year [30] - Adjusted gross margin for the full-year 2025 increased by 140 basis points to 74.2% [36] Business Line Data and Key Metrics Changes - Clinical revenue, excluding biopharma, grew 31% year-over-year in Q4 2025 [16] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [19] - Platform analysis volume was over 105,000 in Q4 2025, a 16% increase from 91,000 in Q4 2024 [30] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4 2025, with clinical revenue up 35% year-over-year [17] - North America saw analysis volumes grow 45% year-over-year in Q4 2025 [17] - Asia Pacific revenue grew 44% in Q4 2025, driven by India and Australia [18] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives like Digital Twins to enhance patient care [12] - SOPHiA GENETICS aims to continue its growth trajectory by leveraging its extensive customer network and enhancing its platform [14] - The transition in leadership to Ross Muken as CEO is expected to drive the next phase of growth [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and a robust pipeline [44] - The company expects full-year 2026 revenue to be between $92 million and $94 million, representing 20%-22% growth [40] - Adjusted EBITDA loss is projected to decrease to between $29 million and $32 million in 2026 [41] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [8] - Annualized revenue churn was at a record low of less than 1% for 2025 [35] - The company raised $15.5 million in net proceeds through an at-the-market facility [33] Q&A Session Questions and Answers Question: What contributions are expected from key growth drivers such as MSK-ACCESS and IMPACT? - Management highlighted that the ramping of MSK-ACCESS continues to be a significant driver, with sizable customers starting to come online [48][49] Question: Can you speak to the net dollar retention increase to 115% and what drove the cross-selling strength? - Management noted that the low churn rate and re-acceleration of volumes in oncology and rare disease contributed to the strong net dollar retention [52][54] Question: What is the potential annual contribution from new pharma contracts? - Management indicated that while the pharma business takes time to ramp, they expect a net positive contribution in 2026 [60][61] Question: How do you assess the potential for the two large health systems added? - Management expressed optimism about the potential for significant growth from these accounts, with opportunities for expansion in the future [63][65]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [28] - Full year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [32] - Gross profit for Q4 was $14.7 million, up 21% from $12.1 million in the prior year [28] - Adjusted gross margin for the full year 2025 was 74.2%, an increase of 140 basis points from 72.8% in 2024 [34] - Annualized revenue churn was less than 1% for 2025, with net dollar retention increasing to 115% [33] Business Line Data and Key Metrics Changes - Clinical revenue excluding biopharma grew 31% year-over-year in Q4 2025 [14] - Hemonc volumes grew 27% year-over-year in Q4, indicating strong performance in hemato-oncology testing [16] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [17] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4, with clinical revenue up 35% year-over-year [15] - North America saw analysis volumes grow 45% year-over-year in Q4 [15] - Asia Pacific revenue grew 44% in Q4, driven by India and Australia [16] - Latin America experienced a recovery with 49% revenue growth in Q4, particularly in Mexico and Brazil [16] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives to modernize its platform [8] - SOPHiA DDM Digital Twins were launched to create AI-driven virtual representations of patients, enhancing treatment decision-making [11] - The company aims to leverage partnerships, such as with MD Anderson, to co-develop new tests and applications [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and a robust pipeline [42] - The company expects full year 2026 revenue to be between $92 million and $94 million, representing 20%-22% growth [38] - Adjusted EBITDA loss is projected to be between $29 million and $32 million for 2026, an improvement from 2025 [39] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [7] - The platform's scalability has improved significantly, allowing for faster and more cost-efficient genomic analysis [9] Q&A Session Summary Question: Contributions from key growth drivers for 2026 - Management highlighted strong performance in Q4 with 31% revenue growth and emphasized the ramping of MSK-ACCESS as a key driver for growth [46][47] Question: Net dollar retention and cross-selling strength - Management noted that the re-acceleration in net dollar retention to 115% reflects the platform's stickiness and the ability to expand within accounts [51][52] Question: Potential annual contribution from new pharma contracts - Management indicated that while the pharma business takes time to ramp, they expect a positive contribution in 2026, with ongoing strategic steps to enhance growth [58][60] Question: Expansion potential with new health systems - Management expressed optimism about the potential for significant growth with the two large health systems, indicating opportunities for expansion beyond initial applications [62][65] Question: Volume price mix for 2026 guidance - Management expects ASPs to increase due to higher-priced tests being sold, while also anticipating volume growth in regions with lower ASPs [70][71] Question: New CEO's approach and potential changes - The new CEO emphasized a focus on scaling the business and unlocking the full value of the platform while maintaining a disciplined investment strategy [73][75]

Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on i ...

Business Strategy and Market Challenges - The company may face challenges in expanding features and applications of its SOPHiA DDM Platform, which is critical for long-term strategy [25]. - The company is expanding its sales and marketing capabilities but faces intense competition for qualified personnel, which may lead to higher fixed costs [37]. - The company’s revenue growth is contingent on the successful adoption of its platform by key opinion leaders and publication of clinical data in peer-reviewed journals [34][35]. - The commercial success of the SOPHiA DDM Platform relies on significant market acceptance, which is uncertain and influenced by various factors such as safety, accuracy, and ease of use compared to competitors [41]. - There is no assurance that the company will successfully penetrate existing markets or expand into new ones, which could adversely affect revenues and operational results [43]. - The addressable market for the SOPHiA DDM Platform may be smaller than estimated, impacting business and financial conditions if actual market size or pricing is lower than projections [44]. - Coverage and reimbursement for new applications and products are uncertain, which could limit the commercial potential of the SOPHiA DDM Platform [45]. - The company anticipates a significant portion of revenue will come from research and development applications, which depend on customer budgets that may be constrained [50]. Financial Performance and Profitability - The company has incurred net losses since inception and expects to continue incurring losses for the foreseeable future, indicating potential difficulties in achieving profitability [28]. - The company reported net losses of $79.0 million and $62.5 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $519.3 million as of December 31, 2025 [194]. - The company expects to continue incurring net losses as it invests in research and development, marketing efforts, and regulatory approvals for its SOPHiA DDM Platform [195]. - The company may need to raise additional capital to fund operations and expand its SOPHiA DDM Platform, which could lead to dilution of existing shareholders' interests [198]. - The company has incurred substantial cash expenditures for research and development and marketing, which are expected to continue in the foreseeable future [197]. - The company may not achieve sustainable gross margins due to rising costs associated with its cloud-native software platform and other operational expenses [204]. Regulatory and Compliance Risks - The company’s ability to obtain regulatory approvals for new features and products is uncertain, which could delay commercialization efforts [32]. - The company intends to seek regulatory clearance for its applications and products to be used as IVDs, which involves a time-consuming and uncertain approval process [97]. - Regulatory authorities have substantial discretion in the clearance and approval process, which may require additional studies and incur significant costs [98]. - The company faces potential regulatory scrutiny and civil penalties if its products are classified under stricter FDA regulations, which could adversely affect its financial condition [107]. - The company is subject to stringent data privacy laws, and non-compliance could result in fines and damage to its reputation [118]. - Compliance with healthcare laws and regulations is costly, and violations could lead to substantial penalties, including exclusion from government-funded healthcare programs [128]. Cybersecurity and Data Privacy - The company faces risks related to cybersecurity and data privacy breaches, which could result in significant liabilities and harm to its brand [27]. - Cybersecurity breaches could lead to significant liabilities and harm the company's reputation, affecting revenue and customer retention [81]. - The company is increasingly dependent on information technologies, which raises the risk of cybersecurity incidents due to deliberate attacks and unauthorized access attempts [82]. - Cybersecurity threats could disrupt the company's operations and compromise the confidentiality and integrity of its data, potentially leading to significant business disruption and data loss [84]. - The company carries cybersecurity insurance, but there is no assurance that potential losses will be covered or will not exceed policy limits [87]. Intellectual Property and Legal Risks - The company relies on its ability to obtain and enforce intellectual property rights to protect its applications and products from competitors [139]. - The company may face challenges from third parties that could invalidate or limit the scope of its patent rights, impacting its competitive position [146]. - The company is currently defending against patent infringement claims from Guardant Health in multiple jurisdictions, which could have significant financial implications [154]. - The company may incur significant expenses from intellectual property litigation, which could distract personnel and negatively affect financial performance [160]. - There is a risk that the company may not secure necessary licenses for third-party intellectual property, which could hinder development and commercialization efforts [167]. Operational and Supply Chain Risks - The company must maintain high performance, security, and reliability of its platform to avoid customer dissatisfaction and potential revenue loss [29]. - The company relies on strategic relationships with third-party providers for distribution, which may not always perform adequately, impacting revenue growth [39]. - The performance of third-party distributors is crucial for sales growth; any termination of distributor relationships could materially affect operations [60]. - The company is dependent on third-party manufacturers for the supply and production of its products, which may impair product advancement and commercialization [65]. - The company may experience supply chain disruptions and interruptions in operations due to geopolitical actions, natural disasters, and public health epidemics [96]. Management and Personnel Risks - The company is highly dependent on its senior management and qualified personnel, which poses a risk if retention becomes an issue [24]. - The company is highly dependent on its senior management team, and the inability to retain key personnel could result in delays in product development and commercialization [71]. - The company competes for resources with other firms, which may lead to delays in clinical studies and impact its development timelines [69]. Market and Competitive Landscape - The company faces competition from established healthcare technology companies that have greater financial resources and market share, impacting its ability to compete effectively [76]. - The company must continuously innovate its SOPHiA DDM Platform to keep pace with rapid advancements in genomics and precision medicine, or risk obsolescence [74]. - The company faces risks in maintaining market acceptance over time, as new cost-effective technologies may emerge, potentially limiting revenue generation [42]. Miscellaneous Risks - The company may face challenges in establishing new manufacturing partnerships, which could result in operational interruptions and affect product delivery [67]. - The company has never paid dividends and does not expect to pay any in the foreseeable future, intending to reinvest earnings into the business [219]. - The market price of the company's ordinary shares has historically been volatile, influenced by factors such as financial condition and operating results [213].

Core Insights - SOPHiA GENETICS reported a fourth quarter revenue of $21.7 million, a 22% increase year-over-year, and a full-year revenue of $77.3 million, up 19% year-over-year, indicating strong growth momentum [1][2] - The company experienced an IFRS net loss of $19.2 million in Q4 2025, a 27% increase from the previous year, and a full-year net loss of $79.0 million, up 26% year-over-year [1][2] - Adjusted gross margin improved to 74.2% in FY 2025, reflecting a 140 basis point increase year-over-year, despite a 40% increase in total terabytes processed by the platform [1][2] Financial Performance - Q4 2025 IFRS net loss: $19.2 million, up 27% YoY; Adjusted EBITDA loss: $9.9 million, up 9% YoY [1] - FY 2025 IFRS net loss: $79.0 million, up 26% YoY; Adjusted EBITDA loss: $41.5 million, up 3% YoY [1] - Gross margin for Q4 2025: 67.7% reported, 73.9% adjusted; FY 2025 gross margin: 67.4% reported, 74.2% adjusted [1][2] Business Highlights - The company signed 124 new core genomics customers in FY 2025, a significant increase from 92 in FY 2024, and achieved a net dollar retention rate of 115% [1][2] - New customer signings included major health systems in the U.S. expected to analyze 60,000 patients annually [1][2] - The company performed over 391,000 analyses in FY 2025, with a record 105,000 analyses in Q4 2025 [1][2] Growth Drivers - Anticipated growth in 2026 will be driven by continued execution in the U.S. market, expansion of the Liquid Biopsy application MSK-ACCESS®, and renewed momentum in the BioPharma business [1][2] - The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [1][2] Strategic Collaborations - A strategic collaboration was announced with MD Anderson Cancer Center to co-develop advanced multimodal oncology testing solutions [1][2] - Continued partnerships with Myriad Genetics and A.D.A.M. Innovations aim to develop MSK-ACCESS® into a regulated global companion diagnostic assay [1][2]

SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026 [Accessibility Statement] Skip NavigationBOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financia ...